Prostate cancer: A review of active surveillance

Research and Reports in Urology

Volumn 6, Issue , 2014, Pages 107-112

  Lund, Lars ^a,b   Svolgaard, Niels ^a   Poulsen, Mads Hvid ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Active surveillance; Prospective studies; Prostate cancer; Review

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; BLOOD LEVEL; CANCER GRADING; CANCER RISK; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; FEASIBILITY STUDY; FOLLOW UP; GLEASON SCORE; HEALTH IMPACT ASSESSMENT; HISTOPATHOLOGY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 84940355197     PISSN: None     EISSN: 22532447     Source Type: Journal    
DOI: 10.2147/RRU.S41653     Document Type: Review

References (37)

1. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol. 2010;184:131-135.
2. Dall'Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976-983.
3. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63:597-603.
4. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124-137.
5. Van den Bergh RC, Korfage IJ, Bangma C.H. Psychological aspects of active surveillance. Curr Opin Urol. 2012;22:237-242.
6. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144-1154.
7. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol. 2013;14:97-108.
8. Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes H.L. Active surveillance for prostate cancer: past, present and future. Curr Opin Oncol. 2012;24:243-250.
9. Boevee SJ, Venderbos LD, Tammela TL, et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer. 2010;46:3082-3089.
10. Bul M, Zhu X, Rannikko A, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol. 2012;62:195-200.
11. Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol. 2013;64: 981-987.
12. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664-2670.
13. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185-2190.
14. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-131.
15. Thomsen FB, Røder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J. 2013;60:A4575.
16. Bratt Ol, Carlsson S, Holmberg E, et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol. 2013;47:347-355.
17. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50:125-128.
18. Thompson IM, Canby-Hagino E, Lucia M.S. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005;97:1236-1237.
19. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
20. Epstein J.I. An update of the Gleason grading system. J Urol. 2010;183: 433-440.
21. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248-1253.
22. Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281: 1395-1400.
23. Epstein J.I. Pathologists should retain their individuality. Am J Surg Pathol. 2000;24:1443-1434.
24. Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer-a systematic review. J Surg Oncol. 2014;109:830-835.
25. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213.
26. Klotz L. Active surveillance: patient selection. Curr Opin Urol. 2013;23:239-244.
27. Adamy A, Yee DS, Matsushita K, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011;185:477-482.
28. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876-892.
29. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28:2810-2816.
30. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011;185:1656-1660.
31. Bangma CH, Bul M, van der Kwast TH, et al. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2013;85:295-302.
32. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27:398-403.
33. Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol. 2013;34:1337-1347.
34. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker C.C. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol. 2014;65:1023-1031.
35. Glass AS, Hilton JF, Cowan JE, Washington SL, Carroll P.R. Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large single-institution active surveillance cohort. Urology. 2014;83:33-38.
36. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer, updated Mar 2013. Available from: http://www.uroweb.org. Accessed March 16, 2014.
37. Thompson I, Brantley JT, Aus G, et al. Prostate cancer, guideline for the management of clinically localized prostate cancer. Available from: http://www.auanet.org. Accessed March 16, 2014.